Bionano Genomics Inc. BNGO, -6.96% shares rallied in the extended session Thursday after the genome analysis company’s quarterly revenue came in better than Wall Street expected. Bionano shares surged 10% after hours, following a 7% decline in the regular session to close at $4.41. The company reported a first-quarter loss of $9.9 million, compared with $10.5 million in the year-ago period. Revenue rose to $3.2 million from $1.1 million in the year-ago quarter. Analysts surveyed by FactSet had forecast revenue of $3 million. “2021 is off to a solid start for Bionano,” said Erik Holmlin, Bionano chief executive, in a statement. “In the first quarter, we sold a record number of flow cells, analyzed a record number of samples in our service lab, drove broad adoption of Saphyr instruments and ramped up the installation of Saphyr systems that weren’t yet operational because of 2020’s travel restrictions.” Bionano’s Saphyr system aids researchers in the development of gene-based drugs.
View Article Origin Here
